Valid Ghana · FDA Ghana

CARBOCISTEINE JUNIOR SYRUP

CARBOCISTEINE JUNIOR

FDA/GD.225-120214 CARBOCISTEINE JUNIOR 125MG/5ML respiratory system

What it does

Carbocisteine is a medication that helps to reduce the thickness of mucus in the airways, making it easier to cough up.

Commonly used for: chronic obstructive pulmonary disease (COPD), bronchitis, asthma

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/GD.225-120214
Registration date
2022-12-07
Expiry date
2027-12-31
Status
Valid
Active ingredient
CARBOCISTEINE JUNIOR
Dosage form
CARBOCISTEINE JUNIOR
Strength
125MG/5ML
Pack size
-
Therapeutic class
-
ATC class (WHO)
R05CB - Mucolytics
Drug group
RESPIRATORY SYSTEM
RxNorm RxCUI
2023
Country of origin
GHANA
Manufacturer location
Plot No.1 Light Industrial Area, Odorkor, Accra, Ghana

Source: Food and Drugs Authority · fetched 2026-04-18 08:33:03 · updated 2026-10-20 04:00:08

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About carbocisteine

Carbocisteine is a medication that helps to reduce the thickness of mucus in the airways, making it easier to cough up.

What it treats

  • chronic obstructive pulmonary disease (COPD)
  • bronchitis
  • asthma

How it works

It works by breaking down and thinning mucus in the lungs, which helps to clear it from the airways.

Who it's for

It is for adults and children with respiratory conditions that involve excessive mucus production.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About junior

Junior is a medication used for various health conditions in children.

What it treats

  • allergies
  • infections
  • fever
  • pain relief

How it works

Junior helps to reduce symptoms by acting on the body’s systems to provide relief.

Who it's for

This medicine is intended for children and should be used as directed by a healthcare professional.

Cautions

  • • Always check with a healthcare provider before use, especially if your child has other health conditions.
  • • Monitor for any allergic reactions or side effects.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Carbocisteine

BNF-referenced

Carbocisteine is a mucolytic agent primarily used to reduce sputum viscosity in conditions such as chronic bronchitis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). It works by restoring the balance of glycoproteins in mucus, thereby improving mucociliary clearance and reducing the risk of respiratory infections.

Indications

  • Chronic bronchitis
  • Cystic fibrosis
  • Chronic obstructive pulmonary disease (COPD)
  • Acute exacerbations of respiratory conditions associated with mucus overproduction

Dosage

Children: For children, the dosage must be determined based on age and weight according to the BNF for Children; refer to the latest guidelines for specific dosing recommendations.

Adults: The usual adult dose is 600 mg once daily, which may vary based on specific conditions and patient response.

Mechanism of action

Carbocisteine acts by stimulating the sialyl transferase enzyme, which helps to restore the equilibrium between sialomucins and fucomucins in bronchial mucus. This mechanism reduces mucus viscosity, enhances mucociliary clearance, and may exhibit antioxidant properties by activating protein kinase B (Akt) phosphorylation, as well as inhibiting inflammatory pathways such as NF-κB and ERK1/2 MAPK. Additionally, it reduces the expression of intracellular adhesion molecule 1 (ICAM-1), which may help limit viral infections in the respiratory tract.

Pharmacodynamics

Carbocisteine is effective in decreasing sputum viscosity, thus alleviating symptoms like cough, dyspnea, and fatigue. Its mucolytic action contributes to the prevention of pulmonary infections by facilitating mucus clearance from the respiratory system. The drug also shows anti-inflammatory properties and reduces oxidative stress, which can be beneficial in respiratory diseases characterized by inflammation.

Pharmacokinetics

Carbocisteine is absorbed from the gastrointestinal tract and has a bioavailability that allows for effective systemic activity. It undergoes metabolic processes in the liver, with metabolites contributing to its therapeutic effects. The elimination half-life and excretion pathways are not specifically detailed, but like many mucolytics, its effects are generally observed within hours after administration.

Contra-indications

  • Active peptic ulceration

Adverse effects

  • Dizziness
  • Fever
  • Headache
  • Nausea
  • Skin reactions

Precautions

  • Use with caution in patients with ischaemic heart disease and stroke

Pregnancy

Manufacturer advises avoid in first trimester. Use only if potential benefit outweighs risk, as toxicity in animal studies has been observed.

Breast-feeding

Manufacturer advises to avoid for 12 hours after administration.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • Carbocisteine 50 mg per 1 ml oral solution sugar-free | 300 ml
  • Carbocisteine 250 mg/5 ml oral solution sugar-free | 300 ml
  • Carbocisteine 375 mg capsules
  • Carbocisteine 750 mg/10 ml solution for injection
BNF 85 (British National Formulary) p.338 BNF for Children 2019-2020 p.209 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: junior

Junior is a term that may refer to a variety of specific medications or formulations aimed at treating pediatric patients. In general, pediatric formulations are designed to cater to the unique pharmacological needs of children, taking into account their developmental stages, metabolism, and dosing requirements. The term can encompass medications used for various conditions such as infections, allergies, and chronic diseases in children.

Indications

  • Infections
  • Allergic reactions
  • Chronic diseases
  • Respiratory conditions
  • Gastrointestinal disorders

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing guidelines.

Adults: Refer to specific medication guidelines or BNF for appropriate adult dosing.

Mechanism of action

The mechanism of action will vary depending on the specific drug referred to as 'junior.' Generally, pediatric medications are designed to target specific receptors, enzymes, or pathways relevant to the condition being treated. For instance, antibiotics may inhibit bacterial cell wall synthesis or protein synthesis, while antihistamines block histamine receptors to alleviate allergy symptoms.

Pharmacodynamics

The pharmacodynamics of pediatric medications often involves understanding the drug's effect on a child's body, which can be significantly different from adults. Children may have different receptor sensitivity, organ maturity, and drug metabolism rates, impacting the efficacy and safety profile of medications. For example, younger children may metabolize drugs faster or slower depending on their age and development.

Pharmacokinetics

Pharmacokinetics in pediatric patients includes the absorption, distribution, metabolism, and excretion of drugs, which can be quite different from adults. Factors such as body surface area, weight, and organ function play crucial roles. For instance, the liver and kidneys, which are responsible for drug metabolism and elimination, may not be fully developed in younger children, necessitating careful consideration in dosing and monitoring.

Pregnancy

Consult a healthcare professional for risk assessment and management.

Breast-feeding

Consult a healthcare professional for safety recommendations.

Storage

Store in a cool, dry place away from direct sunlight.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Carbocisteine

PubChem CID 193653

Molecular formula: C5H9NO4S

Mechanism of action

The hypersecretion of mucus characterizes serious respiratory conditions including asthma, cystic fibrosis (CF), and chronic obstructive pulmonary disease (COPD). It blocks bacterial adherence to cells, preventing pulmonary infections. Glycoproteins (fucomucins, sialomucins and sulfomucins) regulate the viscoelastic properties of bronchial mucus. Increased fucomucins can be found in the mucus of patients with COPD. Carbocisteine serves to restore equilibrium between sialomucins and fucomucins, likely by intracellular stimulation of sialyl transferase enzyme, thus reducing mucus viscosity. A study found that L-carbocisteine can inhibit damage to cells by hydrogen peroxide (H2O2) by activating protein kinase B (Akt) phosphorylation, suggesting that carbocisteine may have antioxidant effects and prevent apoptosis of lung cells. There is some evidence that carbocisteine suppresses NF-κB and ERK1/2 MAPK signalling pathways, reducing TNF-alpha induced inflammation in the lungs, as well as other inflammatory pathways. An in-vitro study found that L-carbocisteine reduces intracellular adhesion molecule 1 (ICAM-1), inhibiting rhinovirus 14 infection, thereby reducing airway inflammation.

Pharmacodynamics

Due to its mucolytic effects, carbocisteine significantly reduces sputum viscosity, cough, dyspnea and fatigue. Additionally, it prevents pulmonary infections by decreasing accumulated mucus in the respiratory tract; this is especially beneficial in preventing exacerbations of COPD caused by bacteria and viruses. It has in-vitro anti-inflammatory activity with some demonstrated action against free radicals.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.